X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (180) 180
humans (177) 177
hematology (103) 103
middle aged (101) 101
leukemia, myeloid, acute - genetics (100) 100
adult (93) 93
male (91) 91
female (89) 89
abridged index medicus (67) 67
prognosis (64) 64
aged (58) 58
mutation (56) 56
oncology (50) 50
adolescent (48) 48
leukemia, myeloid, acute - mortality (43) 43
cancer (41) 41
leukemia (36) 36
young adult (35) 35
acute myeloid-leukemia (33) 33
aged, 80 and over (32) 32
mutations (32) 32
treatment outcome (32) 32
acute myelogenous leukemia (30) 30
animals (30) 30
chromosome aberrations (29) 29
aml (28) 28
leukemia, myeloid, acute - pathology (28) 28
acute myeloid leukemia (27) 27
leukemia, myeloid, acute - drug therapy (27) 27
hemic and lymphatic diseases (26) 26
leukemia, myeloid, acute - therapy (26) 26
mice (24) 24
research (23) 23
survival rate (23) 23
gene expression profiling (22) 22
nuclear proteins - genetics (22) 22
fms-like tyrosine kinase 3 - genetics (21) 21
leukemia, myeloid, acute - diagnosis (21) 21
leukemia, myeloid - genetics (20) 20
leukemia, myeloid, acute - metabolism (20) 20
acute disease (19) 19
gene expression regulation, leukemic (19) 19
prospective studies (19) 19
survival analysis (19) 19
article (18) 18
expression (18) 18
gene expression (18) 18
kaplan-meier estimate (18) 18
karyotyping (18) 18
antineoplastic combined chemotherapy protocols - therapeutic use (17) 17
cell biology (17) 17
group-b (17) 17
in situ hybridization, fluorescence (17) 17
disease-free survival (16) 16
internal tandem duplication (16) 16
younger adults (16) 16
cell line, tumor (15) 15
chemotherapy (15) 15
genetics & heredity (15) 15
normal cytogenetics (15) 15
translocation, genetic (15) 15
adult patients (14) 14
cohort studies (14) 14
mutation - genetics (14) 14
proto-oncogene proteins - genetics (14) 14
acute promyelocytic leukemia (13) 13
biomarkers, tumor - genetics (13) 13
dna mutational analysis (13) 13
dna-binding proteins - genetics (13) 13
favorable prognosis (13) 13
gene (13) 13
myelodysplastic syndromes (13) 13
normal karyotype (13) 13
prognostic-significance (13) 13
cells (12) 12
cytogenetics (12) 12
gene-expression (12) 12
risk factors (12) 12
transcription factors - genetics (12) 12
gene expression regulation, neoplastic (11) 11
genomics (11) 11
homeodomain proteins - genetics (11) 11
leukemia, lymphocytic, chronic, b-cell - genetics (11) 11
proportional hazards models (11) 11
stem cells (11) 11
survival (11) 11
trial (11) 11
alleles (10) 10
analysis (10) 10
biochemistry & molecular biology (10) 10
chromosome deletion (10) 10
dna methylation (10) 10
follow-up studies (10) 10
gene deletion (10) 10
genes (10) 10
genetic aspects (10) 10
medicine, research & experimental (10) 10
myeloid-lymphoid leukemia protein - genetics (10) 10
oligonucleotide array sequence analysis (10) 10
oncogene proteins, fusion - genetics (10) 10
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 06/2016, Volume 374, Issue 23, pp. 2209 - 2221
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2017, Volume 377, Issue 5, pp. 454 - 464
Midostaurin, an oral multitargeted kinase inhibitor, is active in patients with a FLT3 mutation. Among patients with acute myeloid leukemia and this mutation,... 
TRIAL | INTERNAL TANDEM DUPLICATION | WILD-TYPE | MEDICINE, GENERAL & INTERNAL | FAVORABLE PROGNOSIS | ACUTE MYELOGENOUS LEUKEMIA | DISTINCT | TYROSINE KINASE INHIBITOR | SORAFENIB | PHASE-I | YOUNGER | Humans | Middle Aged | Kaplan-Meier Estimate | Staurosporine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Staurosporine - analogs & derivatives | Protein Kinase Inhibitors - adverse effects | Cytarabine - administration & dosage | Leukemia, Myeloid, Acute - mortality | Young Adult | fms-Like Tyrosine Kinase 3 - genetics | Protein Kinase Inhibitors - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Mutation | Daunorubicin - administration & dosage | Leukemia, Myeloid, Acute - genetics | Staurosporine - administration & dosage | Chemotherapy | Care and treatment | Myelocytic leukemia | Nonlymphoid leukemia | Research | Drug therapy | Cancer | Tyrosine | Medical research | Inhibitor drugs | Myeloid leukemia | Leukemia | Clinical trials | Oncology | Transplantation | Kinases | Patients | Cancer therapies | Survival | Cytarabine | Daunorubicin | Medical prognosis | Point mutation | Death | Remission | Acute myeloid leukemia | Protein-tyrosine kinase | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2013, Volume 369, Issue 2, pp. 111 - 121
Journal Article
Nature Medicine, ISSN 1078-8956, 07/2016, Volume 22, Issue 7, pp. 792 - 799
Journal Article
Molecular Cancer, ISSN 1476-4598, 03/2013, Volume 12, Issue 1, pp. 19 - 19
Background: Activating mutations of class III receptor tyrosine kinases (RTK) FLT3, PDGFR and KIT are associated with multiple human neoplasms including... 
PDGFR | Quizartinib | FLT3 | AC220 | Leukemia | KIT | WILD-TYPE | GASTROINTESTINAL STROMAL TUMOR | LIGAND-INDEPENDENT ACTIVATION | BIOCHEMISTRY & MOLECULAR BIOLOGY | C-KIT | ACUTE MYELOID-LEUKEMIA | MYELODYSPLASTIC SYNDROME | SYSTEMIC MASTOCYTOSIS | ONCOLOGY | FLT3 GENE | INTERNAL TANDEM DUPLICATIONS | MAST-CELL LEUKEMIA | fms-Like Tyrosine Kinase 3 - antagonists & inhibitors | Phosphorylation | Apoptosis - drug effects | Humans | Apoptosis - genetics | Leukemia - metabolism | Proto-Oncogene Proteins c-kit - metabolism | Proto-Oncogene Proteins c-kit - antagonists & inhibitors | Dose-Response Relationship, Drug | fms-Like Tyrosine Kinase 3 - genetics | Receptor, Platelet-Derived Growth Factor alpha - antagonists & inhibitors | Inhibitory Concentration 50 | Proto-Oncogene Proteins c-kit - genetics | Antineoplastic Agents - pharmacology | Gastrointestinal Stromal Tumors - genetics | Leukemia - genetics | Receptor, Platelet-Derived Growth Factor alpha - metabolism | Benzothiazoles - pharmacology | fms-Like Tyrosine Kinase 3 - metabolism | Receptor, Platelet-Derived Growth Factor alpha - genetics | Protein Isoforms | Cell Line, Tumor | Gastrointestinal Stromal Tumors - metabolism | Cell Proliferation - drug effects | Phenylurea Compounds - pharmacology | Protein Kinase Inhibitors - pharmacology | Mutation | Tyrosine | Medical research | Platelet-derived growth factor | Codon | Analysis | Medicine, Experimental | Phenols | Pediatrics | Hematology | Software | Kinases | Experiments | Drug dosages | Manuscripts | Index Medicus
Journal Article
Haematologica, ISSN 0390-6078, 03/2012, Volume 97, Issue 3, pp. 393 - 401
Journal Article
Nature Genetics, ISSN 1061-4036, 2014, Volume 46, Issue 1, pp. 33 - 38
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2008, Volume 358, Issue 18, pp. 1909 - 1918
Journal Article
Nature Genetics, ISSN 1061-4036, 12/2016, Volume 48, Issue 12, pp. 1551 - 1556
Journal Article